Reverse Atrial Remodeling in Heart Failure With Recovered Ejection Fraction
Yuxi Sun1,2, Xuefu Chen2, Yanli Zhang2
1Department of Cardiology, West China Hospital Sichuan University Chengdu China.
Journal of the American Heart Association
|January 16, 2023
Summary
Heart failure with recovered ejection fraction (HFrecEF) shows significant left atrial remodeling improvements. Patients with HFrecEF and LA reverse remodeling (LARR) have better outcomes, highlighting LA size as a key prognostic marker.
Area of Science:
- Cardiology
- Echocardiography
- Heart Failure Research
Background:
- Heart failure with recovered ejection fraction (HFrecEF) is a recognized condition, but left atrial (LA) recovery is understudied.
- Current understanding primarily focuses on left ventricular ejection fraction improvement.
Purpose of the Study:
- To investigate changes in left atrial (LA) echocardiographic indices in patients with HFrecEF.
- To assess the prognostic significance of LA reverse remodeling (LARR) in HFrecEF.
Main Methods:
- Retrospective and prospective analysis of an inpatient cohort with heart failure with reduced ejection fraction (HFrEF).
- Classification of patients into HFrecEF and persistent HFrEF groups.
- Echocardiographic assessment of LA parameters and correlation with clinical outcomes.
Main Results:
- The HFrecEF group exhibited significant reductions in LA size and volume compared to persistent HFrEF.
- LA reverse remodeling (LARR) was observed in 59.6% of HFrecEF patients.
- HFrecEF patients with LARR demonstrated a better prognosis, with lower risks of cardiovascular death or heart failure rehospitalization.
Conclusions:
- HFrecEF is associated with improvements in both left ventricular function and left atrial structure.
- LA reverse remodeling (LARR) is a significant predictor of improved clinical outcomes in HFrecEF.
- LA size evaluation serves as a valuable biomarker for risk stratification in heart failure patients.
More Related Videos
Related Concept Videos
01:29Heart Failure II: Pathophysiology
22
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
22
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
481
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
01:25Aortic Regurgitation III: Medical Management
32
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
32